Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses.

Kashyap AS, Fernandez-Rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park SM, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker HC, Zippelius A.

Cell Rep. 2019 Sep 24;28(13):3367-3380.e8. doi: 10.1016/j.celrep.2019.08.057.

2.

Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

Liewen H, Markuly N, Läubli H, Liu Y, Matter MS, Liewen N, Renner C, Zippelius A, Stenner F.

Target Oncol. 2019 Sep 20. doi: 10.1007/s11523-019-00667-z. [Epub ahead of print]

PMID:
31541350
3.

Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4+ T cells.

Dimeloe S, Gubser P, Loeliger J, Frick C, Develioglu L, Fischer M, Marquardsen F, Bantug GR, Thommen D, Lecoultre Y, Zippelius A, Langenkamp A, Hess C.

Sci Signal. 2019 Sep 17;12(599). pii: eaav3334. doi: 10.1126/scisignal.aav3334.

PMID:
31530731
4.

Onkologie – Moderne Diagnostik und Therapie.

Rothschild S, Zippelius A.

Ther Umsch. 2019 Sep;76(4):165. doi: 10.1024/0040-5930/a001079. German. No abstract available.

PMID:
31498039
5.

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Alborelli I, Leonards K, Rothschild SI, Leuenberger LP, Savic Prince S, Mertz KD, Poechtrager S, Buess M, Zippelius A, Läubli H, Haegele J, Tolnay M, Bubendorf L, Quagliata L, Jermann P.

J Pathol. 2019 Aug 30. doi: 10.1002/path.5344. [Epub ahead of print]

PMID:
31471895
6.

Dynamics of Active Filaments in Porous Media.

Mokhtari Z, Zippelius A.

Phys Rev Lett. 2019 Jul 12;123(2):028001. doi: 10.1103/PhysRevLett.123.028001.

PMID:
31386530
7.

Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth In Vitro.

Uda NR, Stenner F, Seibert V, Herzig P, Markuly N, VAN Dijk M, Zippelius A, Renner C.

Anticancer Res. 2019 Aug;39(8):4117-4128. doi: 10.21873/anticanres.13570.

PMID:
31366496
8.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
9.

Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study.

Lengwiler E, Stampf S, Zippelius A, Salati E, Zaman K, Schäfer N, Schardt J, Siano M, Hofbauer G, The Swiss Transplant Cohort Study.

Swiss Med Wkly. 2019 May 19;149:w20078. doi: 10.4414/smw.2019.20078. eCollection 2019 May 6.

10.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402. Erratum in: JAMA Oncol. 2019 Jul 1;5(7):1070.

11.

Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S.

Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15.

PMID:
30988027
12.

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.

Kashyap AS, Thelemann T, Klar R, Kallert SM, Festag J, Buchi M, Hinterwimmer L, Schell M, Michel S, Jaschinski F, Zippelius A.

J Immunother Cancer. 2019 Mar 12;7(1):67. doi: 10.1186/s40425-019-0545-9.

13.

Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC, Tsui YC, Ragusa S, Koelzer VH, Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, Zippelius A, Petrova TV, Mertz K, Ciriello G, Ho PC.

Nat Immunol. 2019 Apr;20(4):515-516. doi: 10.1038/s41590-019-0359-4.

PMID:
30862953
14.

Cancer immunology, inflammation, and tolerance: an introduction.

Dirnhofer S, Zippelius A.

Virchows Arch. 2019 Apr;474(4):405-406. doi: 10.1007/s00428-019-02547-3. No abstract available.

PMID:
30796517
15.

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, Thomas M, Schneller F, Stöhlmacher J, Bernhard H, Gröschel A, Lander T, Probst J, Strack T, Wiegand V, Gnad-Vogt U, Kallen KJ, Hoerr I, von der Muelbe F, Fotin-Mleczek M, Knuth A, Koch SD.

Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15.

PMID:
30770959
16.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H.

Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.

PMID:
30765392
17.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.

J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.

18.

RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types.

Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carré C, Burdin N, Visan L, Ceccarelli M, Poidinger M, Zippelius A, Pedro de Magalhães J, Larbi A.

Cell Rep. 2019 Feb 5;26(6):1627-1640.e7. doi: 10.1016/j.celrep.2019.01.041.

19.

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer.

D'Amico L, Menzel U, Prummer M, Müller P, Buchi M, Kashyap A, Haessler U, Yermanos A, Gébleux R, Briendl M, Hell T, Wolter FI, Beerli RR, Truxova I, Radek Š, Vlajnic T, Grawunder U, Reddy S, Zippelius A.

J Immunother Cancer. 2019 Jan 21;7(1):16. doi: 10.1186/s40425-018-0464-1.

20.

Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.

Cheng WC, Tsui YC, Ragusa S, Koelzer VH, Mina M, Franco F, Läubli H, Tschumi B, Speiser D, Romero P, Zippelius A, Petrova TV, Mertz K, Ciriello G, Ho PC.

Nat Immunol. 2019 Feb;20(2):206-217. doi: 10.1038/s41590-018-0290-0. Epub 2019 Jan 21. Erratum in: Nat Immunol. 2019 Apr;20(4):515-516.

PMID:
30664764
21.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ.

Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.

PMID:
30552023
22.

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

Vetter M, Landin J, Szczerba BM, Castro-Giner F, Gkountela S, Donato C, Krol I, Scherrer R, Balmelli C, Malinovska A, Zippelius A, Kurzeder C, Heinzelmann-Schwarz V, Weber WP, Rochlitz C, Aceto N.

Breast Cancer Res. 2018 Nov 20;20(1):141. doi: 10.1186/s13058-018-1067-y.

23.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
24.

Rheology of Inelastic Hard Spheres at Finite Density and Shear Rate.

Kranz WT, Frahsa F, Zippelius A, Fuchs M, Sperl M.

Phys Rev Lett. 2018 Oct 5;121(14):148002. doi: 10.1103/PhysRevLett.121.148002.

PMID:
30339456
25.

Self-propulsion of droplets driven by an active permeating gel.

Kree R, Zippelius A.

Eur Phys J E Soft Matter. 2018 Oct 11;41(10):118. doi: 10.1140/epje/i2018-11729-1.

PMID:
30302661
26.

Linear rheology of reversibly cross-linked biopolymer networks.

Amuasi HE, Fischer A, Zippelius A, Heussinger C.

J Chem Phys. 2018 Aug 28;149(8):084902. doi: 10.1063/1.5030169.

PMID:
30193493
27.

Stress auto-correlation tensor in glass-forming isothermal fluids: From viscous to elastic response.

Maier M, Zippelius A, Fuchs M.

J Chem Phys. 2018 Aug 28;149(8):084502. doi: 10.1063/1.5044662.

PMID:
30193479
28.

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.

Ortega Sanchez G, Jahn K, Savic S, Zippelius A, Läubli H.

J Immunother Cancer. 2018 Sep 3;6(1):85. doi: 10.1186/s40425-018-0400-4.

29.

Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy.

Läubli H, Dirnhofer S, Zippelius A.

Virchows Arch. 2019 Apr;474(4):485-495. doi: 10.1007/s00428-018-2435-9. Epub 2018 Aug 25.

PMID:
30143868
30.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

31.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A.

Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11.

32.

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.

Läubli H, Balmelli C, Kaufmann L, Stanczak M, Syedbasha M, Vogt D, Hertig A, Müller B, Gautschi O, Stenner F, Zippelius A, Egli A, Rothschild SI.

J Immunother Cancer. 2018 May 22;6(1):40. doi: 10.1186/s40425-018-0353-7.

33.

Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.

Rothschild U, Muller L, Lechner A, Schlösser HA, Beutner D, Läubli H, Zippelius A, Rothschild SI.

Swiss Med Wkly. 2018 May 14;148:w14625. doi: 10.4414/smw.2018.14625. eCollection 2018. Review.

34.

The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.

Läubli H, Müller P, D'Amico L, Buchi M, Kashyap AS, Zippelius A.

Cancer Immunol Immunother. 2018 May;67(5):815-824. doi: 10.1007/s00262-018-2136-x. Epub 2018 Feb 27.

PMID:
29487979
35.

Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.

Murekatete B, Shokoohmand A, McGovern J, Mohanty L, Meinert C, Hollier BG, Zippelius A, Upton Z, Kashyap AS.

Sci Rep. 2018 Jan 12;8(1):583. doi: 10.1038/s41598-017-19073-4.

36.

Emergence of Long-Ranged Stress Correlations at the Liquid to Glass Transition.

Maier M, Zippelius A, Fuchs M.

Phys Rev Lett. 2017 Dec 29;119(26):265701. doi: 10.1103/PhysRevLett.119.265701. Epub 2017 Dec 29.

PMID:
29328698
37.

The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.

Läubli H, Koelzer VH, Matter MS, Herzig P, Dolder Schlienger B, Wiese MN, Lardinois D, Mertz KD, Zippelius A.

Oncoimmunology. 2017 Oct 26;7(2):e1386362. doi: 10.1080/2162402X.2017.1386362. eCollection 2018.

38.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

39.

Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.

Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F.

J Immunother Cancer. 2017 Jun 20;5:46. doi: 10.1186/s40425-017-0249-y. eCollection 2017.

40.

Density-wave fronts on the brink of wet granular condensation.

Zippelius A, Huang K.

Sci Rep. 2017 Jun 15;7(1):3613. doi: 10.1038/s41598-017-03844-0.

41.

Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy.

Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Müller P, Kreuzaler M, Lu M, Favre S, Kreppel F, Löhning M, Luther SA, Zippelius A, Merkler D, Pinschewer DD.

Nat Commun. 2017 May 26;8:15327. doi: 10.1038/ncomms15327.

42.

[The pathology of adverse events with immune checkpoint inhibitors].

Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD.

Pathologe. 2017 May;38(3):197-208. doi: 10.1007/s00292-017-0281-1. Review. German.

PMID:
28421272
43.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
44.

Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort.

Conen K, Hagmann R, Hess V, Zippelius A, Rothschild SI.

J Cancer. 2016 Oct 23;7(14):2110-2116. eCollection 2016.

45.

Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies
.

Müller P, Thommen DS, Zippelius A.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):692-694. doi: 10.5414/CPXCES15EA06. No abstract available.

PMID:
27641216
46.

Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.

Ruiz C, Kustermann S, Pietilae E, Vlajnic T, Baschiera B, Arabi L, Lorber T, Oeggerli M, Savic S, Obermann E, Singer T, Rothschild SI, Zippelius A, Roth AB, Bubendorf L.

PLoS One. 2016 Aug 22;11(8):e0160807. doi: 10.1371/journal.pone.0160807. eCollection 2016.

47.

Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.

Koelzer VH, Buser T, Willi N, Rothschild SI, Wicki A, Schiller P, Cathomas G, Zippelius A, Mertz KD.

J Immunother Cancer. 2016 Aug 16;4:47. doi: 10.1186/s40425-016-0151-z. eCollection 2016.

48.

Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.

Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M.

Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May.

49.

Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.

Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M.

Cancer Immunol Res. 2016 Sep 2;4(9):744-54. doi: 10.1158/2326-6066.CIR-15-0156. Epub 2016 Jul 27.

50.

Elasticity of a semiflexible filament with a discontinuous tension due to a cross-link or a molecular motor.

Razbin M, Benetatos P, Zippelius A.

Phys Rev E. 2016 May;93(5):052408. doi: 10.1103/PhysRevE.93.052408. Epub 2016 May 18.

PMID:
27300925

Supplemental Content

Loading ...
Support Center